The Role of Glial Reaction and Inflammation in Parkinson's Disease
Identifieur interne : 001F03 ( Istex/Curation ); précédent : 001F02; suivant : 001F04The Role of Glial Reaction and Inflammation in Parkinson's Disease
Auteurs : E. C. Hirsch [France] ; T. Breidert [France] ; E. Rousselet [France] ; S. Hunot [France] ; A. Hartmann [France] ; P. P. Michel [France]Source :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2003-06.
English descriptors
- KwdEn :
Abstract
Abstract: The glial reaction is generally considered to be a consequence of neuronal death in neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease. In Parkinson's disease, postmortem examination reveals a loss of dopaminergic neurons in the substantia nigra associated with a massive astrogliosis and the presence of activated microglial cells. Recent evidence suggests that the disease may progress even when the initial cause of neuronal degeneration has disappeared, suggesting that toxic substances released by the glial cells may be involved in the propagation and perpetuation of neuronal degeneration. Glial cells can release deleterious compounds such as proinflammatory cytokines (TNF‐α, Il‐1β, IFN‐γ), which may act by stimulating nitric oxide production in glial cells, or which may exert a more direct deleterious effect on dopaminergic neurons by activating receptors that contain intracytoplasmic death domains involved in apoptosis. In line with this possibility, an activation of proteases such as caspase‐3 and caspase‐8, which are known effectors of apoptosis, has been reported in Parkinson's disease. Yet, caspase inhibitors or invalidation of TNF‐α receptors does not protect dopaminergic neurons against degeneration in experimental models of the disease, suggesting that manipulation of a single signaling pathway may not be sufficient to protect dopaminergic neurons. In contrast, the antiinflammatory drugs pioglitazone, a PPAR‐γ agonist, and the tetracycline derivative minocycline have been shown to reduce glial activation and protect the substantia nigra in an animal model of the disease. Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease.
Url:
DOI: 10.1111/j.1749-6632.2003.tb07478.x
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F05
Links to Exploration step
ISTEX:7EC790141B211503BA4D587100832AD9E681C8B0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Role of Glial Reaction and Inflammation in Parkinson's Disease</title>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>E-mail: hirsch@ccr.jussieu.fr</mods:affiliation>
<country wicri:rule="url">France</country>
</affiliation>
</author>
<author><name sortKey="Breidert, T" sort="Breidert, T" uniqKey="Breidert T" first="T." last="Breidert">T. Breidert</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rousselet, E" sort="Rousselet, E" uniqKey="Rousselet E" first="E." last="Rousselet">E. Rousselet</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hunot, S" sort="Hunot, S" uniqKey="Hunot S" first="S." last="Hunot">S. Hunot</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hartmann, A" sort="Hartmann, A" uniqKey="Hartmann A" first="A." last="Hartmann">A. Hartmann</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Michel, P P" sort="Michel, P P" uniqKey="Michel P" first="P. P." last="Michel">P. P. Michel</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7EC790141B211503BA4D587100832AD9E681C8B0</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1111/j.1749-6632.2003.tb07478.x</idno>
<idno type="url">https://api.istex.fr/document/7EC790141B211503BA4D587100832AD9E681C8B0/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F05</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F05</idno>
<idno type="wicri:Area/Istex/Curation">001F03</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The Role of Glial Reaction and Inflammation in Parkinson's Disease</title>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>E-mail: hirsch@ccr.jussieu.fr</mods:affiliation>
<country wicri:rule="url">France</country>
</affiliation>
</author>
<author><name sortKey="Breidert, T" sort="Breidert, T" uniqKey="Breidert T" first="T." last="Breidert">T. Breidert</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rousselet, E" sort="Rousselet, E" uniqKey="Rousselet E" first="E." last="Rousselet">E. Rousselet</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hunot, S" sort="Hunot, S" uniqKey="Hunot S" first="S." last="Hunot">S. Hunot</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hartmann, A" sort="Hartmann, A" uniqKey="Hartmann A" first="A." last="Hartmann">A. Hartmann</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Michel, P P" sort="Michel, P P" uniqKey="Michel P" first="P. P." last="Michel">P. P. Michel</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, 75651 Paris Cedex 13</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the New York Academy of Sciences</title>
<idno type="ISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2003-06">2003-06</date>
<biblScope unit="volume">991</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="214">214</biblScope>
<biblScope unit="page" to="228">228</biblScope>
</imprint>
<idno type="ISSN">0077-8923</idno>
</series>
<idno type="istex">7EC790141B211503BA4D587100832AD9E681C8B0</idno>
<idno type="DOI">10.1111/j.1749-6632.2003.tb07478.x</idno>
<idno type="ArticleID">NYAS214</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0077-8923</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>apoptosis</term>
<term>cytokines</term>
<term>dopamine neuron</term>
<term>neuroprotection</term>
<term>substantia nigra</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Abstract: The glial reaction is generally considered to be a consequence of neuronal death in neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease. In Parkinson's disease, postmortem examination reveals a loss of dopaminergic neurons in the substantia nigra associated with a massive astrogliosis and the presence of activated microglial cells. Recent evidence suggests that the disease may progress even when the initial cause of neuronal degeneration has disappeared, suggesting that toxic substances released by the glial cells may be involved in the propagation and perpetuation of neuronal degeneration. Glial cells can release deleterious compounds such as proinflammatory cytokines (TNF‐α, Il‐1β, IFN‐γ), which may act by stimulating nitric oxide production in glial cells, or which may exert a more direct deleterious effect on dopaminergic neurons by activating receptors that contain intracytoplasmic death domains involved in apoptosis. In line with this possibility, an activation of proteases such as caspase‐3 and caspase‐8, which are known effectors of apoptosis, has been reported in Parkinson's disease. Yet, caspase inhibitors or invalidation of TNF‐α receptors does not protect dopaminergic neurons against degeneration in experimental models of the disease, suggesting that manipulation of a single signaling pathway may not be sufficient to protect dopaminergic neurons. In contrast, the antiinflammatory drugs pioglitazone, a PPAR‐γ agonist, and the tetracycline derivative minocycline have been shown to reduce glial activation and protect the substantia nigra in an animal model of the disease. Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001F03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:7EC790141B211503BA4D587100832AD9E681C8B0 |texte= The Role of Glial Reaction and Inflammation in Parkinson's Disease }}
This area was generated with Dilib version V0.6.29. |